Equilab International is the first CRO in Indonesia as well as the first CRO in South East Asia that got approval from WHO.
They have established their end-to-end services for customers from all around the globe by providing the services for clinical trial, central lab, pharmacokinetics and bioavailability studies, and dermatology studies. Equilab International has completed more than 1,000 clinical studies. At the heart of this proven track record of success is its expertise and dedicated facilities, which boost a pharma and biologics company’s clinical study with accurate and timely data that aligns with their project deadlines and required international regulations. Equilab International’s success in conducting large-scale clinical trials can also be attributed to Indonesia’s populace, which comprises over 300 ethnicities and prevalence of a wide range of diseases, allowing consistent recruitment of patients for various drug development projects, and their successful story to get Material Transfer Agreement (MTA) from Indonesian MOH.
During the pandemic, Equilab successfully managed more than 10 vaccine trials with a large number of participants (up to 9,500/study), which shows their expertise as a global clinical trial company capable of managing large studies. Besides vaccine trials, they also has extensive experiences in hormonal, nutritional, cardiovascular, endocrine, oncology, and dermatology clinical trials.
Having an accredited facility, Equilab International is also the choice for central laboratory and pharmacokinetics laboratory. The complete set of skillful operation team and acknowledged facility has made Equilab International become the leading CRO in Southeast Asia.